SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

OBI Pharma Signs ADC Collaboration and License Agreement with Novartis

OBI Pharma says it entered a collaboration and license agreement with Novartis Pharma AG to develop next-generation antibody-drug conjugates using novel payloads and OBI’s technology suite.

4174NOVN

TAIPEI, TW / / November 16, 2026 / OBI Pharma, Inc. (4174.TWO) ("OBI") announced that it has entered into a Collaboration and License agreement with Novartis Pharma AG ("Novartis") to develop next generation Antibody-Drug-Conjugates (ADCs) with novel payloads, using OBI's suite of p…

Related stories